Lanoxin
(Digoxin)ApprovedSmall molecule
Digoxin is used to treat heart failure and irregular heartbeats by making the heart beat stronger and more regularly. It helps the heart pump blood more effectively throughout the body.[2] Lanoxin is currently approved and in use across 31 indications[4].[1]
Lanoxin is one of 755 small molecule programs targeting HIV infection. It is currently in Approved.
31
Indications
182
Total Trials
18
Active Trials
754
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 31 indications
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Lanoxin
AAdvanz Pharma
Approved
TQB2450
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Huaier Granule
QQidong Gaitianli Medicines Co., Ltd
Phase 3
YL202
MMediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Interaction46 trials
Show 43 more trials
Tics8 trials
Show 5 more trials
Atrial Fibrillation7 trials
Show 4 more trials
Heart Failure6 trials
Show 3 more trials
Efficacy Study of Digoxin & Ivabradine to Treat Heart Failure
Completed·—·Phase 4·NCT01699776·22 enrolled
Single Dose5 trials
Show 2 more trials
65 more indications
Adult4 trials
Atorvastatin4 trials
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1·NCT06601517·30 enrolled
Midazolam4 trials
ART4 trials
Concentration3 trials
Breast Cancer3 trials
DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01763931·6 enrolled
Drug Interactions3 trials
Metformin3 trials
Statin2 trials
Drug Transporter2 trials
Gastric Emptying2 trials
Adult Subject2 trials
Phase 12 trials
Clinical Trial2 trials
Female2 trials
Prostate Cancer2 trials
Digoxin for Recurrent Prostate Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01162135·16 enrolled
Drug Metabolism2 trials
Supraventricular tachycardia2 trials
Phase II1 trial
Malignant Tumors1 trial
Dapagliflozin1 trial
Overweight or Obese1 trial
NASH1 trial
Head and Neck Cancer1 trial
Gastrointestinal1 trial
Type 2 Diabetes Mellitus1 trial
Dilation and Evacuation1 trial
Drug1 trial
TED1 trial
Metastatic Melanoma1 trial
Methotrexate1 trial
Congenital Heart Disease1 trial
Advanced Solid Tumor1 trial
Alveolar Soft Part Sarcoma1 trial
Rheumatoid Arthritis1 trial
Thyroid Carcinoma1 trial
Spironolactone1 trial
Overweight1 trial
Cirrhosis1 trial
Advanced Solid Tumors1 trial
Caffeine1 trial
Solid Tumors1 trial
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
Active, not recruiting·—·Phase 1·NCT03889795·15 enrolled
Colorectal Cancer1 trial
AIN1 trial
Semaglutide1 trial
Acute Heart Failure1 trial
Pancreas Cancer1 trial
Advanced Solid Malignancies1 trial
Urinary Bladder Neoplasms1 trial
Obesity1 trial
Unspecified16 trials
Show 13 more trials
A Phase 1 Clinical Trial in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Embibatinib, the Effects of Food, Acid-Reducing Agents, and Drug-Drug Interactions, and the Relative Bioavailability of New Tablet Formulations of Embibatinib.
Completed·TTerns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·Phase 1·NCT07838987·196 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
LANOXIN
NDA NDA009330
Jul 26, 1982
LANOXICAPS
NDA NDA018118
Sep 30, 1997
LANOXIN
NDA NDA020405
Aug 26, 2004
DIGOXIN
NDA NDA021648
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lanoxin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Digoxin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Sodium/potassium-Transporting Atpase Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- AAdvanz Pharma